Symbols / ENSC Stock $0.58 -8.92%
ENSC (Stock) Chart
About
Asset: Stock
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.09M |
| Enterprise Value | 621.43K | Income | -10.97M | Sales | 4.49M |
| Book/sh | 0.38 | Cash/sh | 0.47 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -0.26 | PEG | — |
| P/S | 0.47 | P/B | 1.52 | P/C | — |
| EV/EBITDA | — | EV/Sales | 0.14 | Quick Ratio | 0.73 |
| Current Ratio | 1.27 | Debt/Eq | 44.32 | LT Debt/Eq | — |
| EPS (ttm) | -6.35 | EPS next Y | -2.23 | EPS Growth | — |
| Revenue Growth | -85.60% | Earnings | 2025-11-14 16:00 | ROA | -109.79% |
| ROE | -294.39% | ROIC | — | Gross Margin | -135.44% |
| Oper. Margin | -7.59% | Profit Margin | -244.49% | Shs Outstand | 3.63M |
| Shs Float | 3.11M | Short Float | 9.02% | Short Ratio | 0.02 |
| Short Interest | — | 52W High | 4.85 | 52W Low | 0.31 |
| Beta | 1.16 | Avg Volume | 6.26M | Volume | 1.35M |
| Target Price | $16.45 | Recom | None | Prev Close | $0.63 |
| Price | $0.57 | Change | -8.92% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.45
Mean price target
2. Current target
$0.52
Latest analyst target
3. DCF / Fair value
$-15.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.52
Low
$16.45
High
$16.45
Mean
$16.45
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-09-25 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-07-03 | init | HC Wainwright & Co. | — → Buy | $9 |
- CEO takes live questions on Ensysce PF614 pain-drug plans - Stock Titan Wed, 04 Mar 2026 08
- ENSC Surges 15.5% Without Clear Catalyst - Bitget Wed, 18 Mar 2026 17
- ENSC Ensysce Biosciences NASDAQ up 54.50% intraday 27 Feb 2026: volume spike - Meyka Fri, 27 Feb 2026 08
- Market Movers | Winners: KORE, ENSC, AAOI | Losers: ARTC, RNA, RPGL - Trefis Sat, 28 Feb 2026 08
- New opioid design limits drug release when too many pills are swallowed - Stock Titan ue, 03 Mar 2026 08
- Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView Fri, 27 Feb 2026 08
- Should You Buy Ensysce Biosciences After Share Sale? - StocksToTrade ue, 09 Dec 2025 08
- Is Ensysce Biosciences a Hidden Gem? - timothysykes.com ue, 09 Dec 2025 08
- ENSC stock touches 52-week low at $1.7 amid market challenges - Investing.com Mon, 21 Apr 2025 07
- Drug developer Ensysce invited to 2026 pain and substance use research forums - Stock Titan Mon, 23 Feb 2026 08
- Opioid safety drug developer Ensysce explores deals, possible asset sales - Stock Titan Wed, 25 Feb 2026 08
- Opioid designed to stay inactive until swallowed hits Phase 3 milestone - Stock Titan Wed, 28 Jan 2026 08
- Nasdaq warns Ensysce Biosciences (ENSC) over sub-$1 minimum bid price - Stock Titan Fri, 27 Feb 2026 08
- Inside a biotech developing pain pills with built-in overdose protection - Stock Titan Mon, 05 Jan 2026 08
- New Brazil patent backs Ensysce bid for safer opioid pain drugs - Stock Titan Wed, 21 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.70M | -10.27M | -24.10M | -25.53M |
| TotalUnusualItems | 430.44K | 5.76M | -2.32M | |
| TotalUnusualItemsExcludingGoodwill | 430.44K | 5.76M | -2.32M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.99M | -10.61M | -24.17M | -29.08M |
| ReconciledDepreciation | 0.00 | 151.00 | ||
| EBITDA | -6.70M | -10.27M | -24.10M | -27.85M |
| EBIT | -6.70M | -10.27M | -24.10M | -27.85M |
| NetInterestIncome | -1.29M | -353.94K | -4.98M | -5.08M |
| InterestExpense | 1.29M | 353.94K | 109.53K | 1.30M |
| NormalizedIncome | -7.99M | -10.61M | -24.17M | -26.76M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.99M | -10.61M | -24.17M | -29.08M |
| TotalExpenses | 6.73M | 10.72M | 24.22M | 19.87M |
| TotalOperatingIncomeAsReported | -6.73M | -10.72M | -24.22M | -19.87M |
| DilutedAverageShares | 1.36M | 150.94K | 35.63K | 5.61K |
| BasicAverageShares | 1.36M | 150.94K | 35.63K | 5.61K |
| DilutedEPS | -11.45 | -70.40 | -2.09K | -5.33K |
| BasicEPS | -11.45 | -70.40 | -2.09K | -5.33K |
| DilutedNIAvailtoComStockholders | -7.99M | -10.63M | -25.09M | -29.89M |
| NetIncomeCommonStockholders | -7.99M | -10.63M | -25.09M | -29.89M |
| OtherunderPreferredStockDividend | 290.00 | 12.94K | 913.20K | 803.14K |
| NetIncome | -7.99M | -10.61M | -24.17M | -29.08M |
| MinorityInterests | 74.00 | 13.20K | 35.39K | 62.19K |
| NetIncomeIncludingNoncontrollingInterests | -7.99M | -10.63M | -24.21M | -29.15M |
| NetIncomeContinuousOperations | -7.99M | -10.63M | -24.21M | -29.15M |
| PretaxIncome | -7.99M | -10.63M | -24.21M | -29.15M |
| OtherIncomeExpense | 33.57K | 445.86K | 5.00M | -4.19M |
| OtherNonOperatingIncomeExpenses | 33.57K | 445.86K | 5.00M | -1.87M |
| SpecialIncomeCharges | 146.48K | 1.79M | -154.39K | |
| OtherSpecialCharges | -146.48K | -1.79M | 154.39K | |
| GainOnSaleOfSecurity | 283.96K | 5.76M | -2.32M | |
| NetNonOperatingInterestIncomeExpense | -1.29M | -353.94K | -4.98M | -5.08M |
| TotalOtherFinanceCost | 4.88M | 3.79M | ||
| InterestExpenseNonOperating | 1.29M | 353.94K | 109.53K | 1.30M |
| OperatingIncome | -6.73M | -10.72M | -24.22M | -19.87M |
| OperatingExpense | 6.73M | 10.72M | 24.22M | 19.87M |
| OtherOperatingExpenses | -5.21M | -2.23M | -2.52M | -3.53M |
| ResearchAndDevelopment | 7.22M | 7.59M | 19.84M | 4.69M |
| SellingGeneralAndAdministration | 4.72M | 5.36M | 6.91M | 18.71M |
| GeneralAndAdministrativeExpense | 4.72M | 5.36M | 6.91M | 18.71M |
| OtherGandA | 4.72M | 5.36M | 6.91M | 18.71M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 6.00 | 5.00 | ||
| OrdinarySharesNumber | 1.36M | 209.74K | 35.63K | 6.84K |
| ShareIssued | 1.36M | 209.74K | 35.63K | 6.84K |
| NetDebt | 1.26M | 4.92M | ||
| TotalDebt | 301.66K | 854.70K | 4.43M | 17.21M |
| TangibleBookValue | 3.71M | -322.86K | -3.71M | -7.88M |
| InvestedCapital | 4.01M | 531.84K | 692.31K | 9.31M |
| WorkingCapital | 3.14M | -1.04M | -4.17M | -819.07K |
| NetTangibleAssets | 3.71M | -322.86K | -3.71M | -7.88M |
| CapitalLeaseObligations | 0.00 | 27.32K | 24.87K | |
| CommonStockEquity | 3.71M | -322.86K | -3.71M | -7.88M |
| TotalCapitalization | 3.71M | -322.86K | -3.57M | -3.44M |
| TotalEquityGrossMinorityInterest | 3.38M | -651.27K | -4.03M | -8.16M |
| MinorityInterest | -328.48K | -328.41K | -315.21K | -279.81K |
| StockholdersEquity | 3.71M | -322.86K | -3.71M | -7.88M |
| RetainedEarnings | -129.54M | -121.56M | -110.93M | -85.85M |
| AdditionalPaidInCapital | 133.25M | 121.23M | 107.22M | 77.97M |
| CapitalStock | 136.00 | 21.00 | 53.00 | 124.00 |
| CommonStock | 136.00 | 21.00 | 53.00 | 124.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.22M | 3.36M | 9.91M | 24.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.10K | 26.39K | 450.49K | 8.09M |
| OtherNonCurrentLiabilities | 349.20K | |||
| DerivativeProductLiabilities | 10.10K | 26.39K | 310.35K | 3.30M |
| LongTermDebtAndCapitalLeaseObligation | 140.15K | 4.44M | ||
| LongTermDebt | 140.15K | 4.44M | ||
| CurrentLiabilities | 2.21M | 3.33M | 9.46M | 16.48M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 301.66K | 854.70K | 4.29M | 12.77M |
| CurrentCapitalLeaseObligation | 0.00 | 27.32K | 24.87K | |
| CurrentDebt | 301.66K | 854.70K | 4.27M | 12.75M |
| OtherCurrentBorrowings | 301.66K | 854.70K | 4.27M | 12.75M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 0.00 | 1.34M | ||
| PayablesAndAccruedExpenses | 1.91M | 2.48M | 5.17M | 3.71M |
| CurrentAccruedExpenses | 548.46K | 542.26K | 2.23M | 3.41M |
| Payables | 1.36M | 1.94M | 2.94M | 301.10K |
| AccountsPayable | 1.36M | 1.94M | 2.94M | 301.10K |
| TotalAssets | 5.60M | 2.71M | 5.89M | 16.42M |
| TotalNonCurrentAssets | 252.55K | 419.22K | 585.88K | 754.76K |
| OtherNonCurrentAssets | 252.55K | 419.22K | 585.88K | 754.76K |
| NetPPE | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 5.34M | 2.29M | 5.30M | 15.66M |
| OtherCurrentAssets | 18.00K | 18.00K | 27.16K | 24.72K |
| PrepaidAssets | 1.70M | 1.05M | 1.85M | 2.93M |
| Receivables | 124.11K | 97.56K | 276.82K | 441.72K |
| OtherReceivables | 124.11K | 97.56K | 276.82K | 441.72K |
| CashCashEquivalentsAndShortTermInvestments | 3.50M | 1.12M | 3.15M | 12.26M |
| CashAndCashEquivalents | 3.50M | 1.12M | 3.15M | 12.26M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.50M | -10.78M | -17.89M | -8.24M |
| RepaymentOfDebt | -485.19K | -1.00M | -1.41M | -467.77K |
| IssuanceOfDebt | 0.00 | 1.61M | 7.53M | 14.38M |
| IssuanceOfCapitalStock | 1.67M | 9.05M | 3.78M | 6.63M |
| IncomeTaxPaidSupplementalData | 3.20K | 3.20K | 1.60K | 1.60K |
| EndCashPosition | 3.50M | 1.12M | 3.15M | 12.26M |
| BeginningCashPosition | 1.12M | 3.15M | 12.26M | 194.21K |
| ChangesInCash | 2.38M | -2.02M | -9.12M | 12.07M |
| FinancingCashFlow | 9.88M | 8.76M | 8.77M | 20.31M |
| CashFlowFromContinuingFinancingActivities | 9.88M | 8.76M | 8.77M | 20.31M |
| NetOtherFinancingCharges | -1.84M | -899.55K | -1.14M | -488.54K |
| ProceedsFromStockOptionExercised | 10.54M | 0.00 | 0.00 | 262.86K |
| NetCommonStockIssuance | 1.67M | 9.05M | 3.78M | 6.63M |
| CommonStockIssuance | 1.67M | 9.05M | 3.78M | 6.63M |
| NetIssuancePaymentsOfDebt | -485.19K | 605.43K | 6.13M | 13.91M |
| NetLongTermDebtIssuance | -485.19K | 605.43K | 6.13M | 13.91M |
| LongTermDebtPayments | -485.19K | -1.00M | -1.41M | -467.77K |
| LongTermDebtIssuance | 0.00 | 1.61M | 7.53M | 14.38M |
| InvestingCashFlow | 0.00 | 4.50K | 0.00 | |
| CashFlowFromContinuingInvestingActivities | 0.00 | 4.50K | 0.00 | |
| NetOtherInvestingChanges | 4.50K | |||
| OperatingCashFlow | -7.50M | -10.78M | -17.89M | -8.24M |
| CashFlowFromContinuingOperatingActivities | -7.50M | -10.78M | -17.89M | -8.24M |
| ChangeInWorkingCapital | -851.25K | -947.08K | 5.48M | -1.30M |
| ChangeInPayablesAndAccruedExpense | -572.73K | -2.52M | 3.66M | 754.25K |
| ChangeInAccruedExpense | 6.20K | -1.28M | 1.02M | 2.18M |
| ChangeInPayable | -578.93K | -1.23M | 2.64M | -1.42M |
| ChangeInAccountPayable | -578.93K | -1.23M | 2.64M | -1.42M |
| ChangeInPrepaidAssets | -251.97K | 1.39M | 1.65M | -1.62M |
| ChangeInReceivables | -26.55K | 179.26K | 164.90K | -441.72K |
| OtherNonCashItems | 1.24M | 344.65K | 8.29M | 7.33M |
| StockBasedCompensation | 110.72K | 879.16K | 1.07M | 121.76K |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | -146.48K | -1.79M | |
| DepreciationAmortizationDepletion | 0.00 | 151.00 | ||
| DepreciationAndAmortization | 0.00 | 151.00 | ||
| Depreciation | 0.00 | 151.00 | ||
| OperatingGainsLosses | -16.29K | -283.96K | -6.74M | 14.75M |
| GainLossOnInvestmentSecurities | -16.29K | -283.96K | -6.73M | 14.25M |
| NetIncomeFromContinuingOperations | -7.99M | -10.63M | -24.21M | -29.15M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ENSC
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|